State of Alaska Department of Revenue Trims Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Alaska Department of Revenue decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 14,268 shares of the biopharmaceutical company’s stock after selling 1,410 shares during the period. State of Alaska Department of Revenue’s holdings in Halozyme Therapeutics were worth $527,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Advisory Services Network LLC lifted its position in shares of Halozyme Therapeutics by 50.5% in the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 303 shares during the period. Belpointe Asset Management LLC lifted its holdings in Halozyme Therapeutics by 42.0% in the first quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 366 shares during the period. Harbour Investments Inc. bought a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $51,000. Acadian Asset Management LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $92,000. Finally, Mendota Financial Group LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $127,000. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

HALO opened at $38.61 on Friday. The firm has a market cap of $4.91 billion, a PE ratio of 18.30, a P/E/G ratio of 0.47 and a beta of 1.25. The stock has a 50-day moving average price of $39.22 and a 200-day moving average price of $37.77. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HALO shares. HC Wainwright lifted their price target on Halozyme Therapeutics from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. TheStreet cut shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. Finally, Benchmark restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Friday, January 19th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.29.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.